Depomed (DEPO) Tops Q1 EPS by 11c

Depomed (NASDAQ: DEPO) reported Q1 EPS of $0.28, $0.11 better than the analyst estimate of $0.17. Revenue for the quarter came in at $63.46 million versus the consensus estimate of $65.7 million.

Financial Highlights

• First-quarter GAAP revenues were $128.4 million(1)
• First-quarter GAAP net income of $33.8 million or $0.48 per share
• First-quarter non-GAAP adjusted EBITDA of $31.8 million
• First-quarter ending cash and marketable securities of $101.7 million

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c